Bone and soft tissue sarcomas, tumors of the skinBone and soft tissue sarcomas, tumors of the skinСаркомы костей, мягких тканей и опухоли кожи2219-46142782-3687Publishing House ABV Press60610.17650/2219-4614-2023-15-2-18-24TUMORS OF THE SKINОПУХОЛИ КОЖИSurgical options in melanoma metastasis in regional lymph nodesХирургические опции при метастазах меланомы кожи в регионарные лимфатические узлыhttps://orcid.org/0000-0002-2976-8895BukharovA. V.БухаровА. В.
Russian Federation

3 2nd Botkinsky proezd, Moscow 125284

125284 Москва, 2-й Боткинский проезд, 3

https://orcid.org/0000-0002-3501-036XErinD. A.ЕринД. А.
Russian Federation

3 2nd Botkinsky proezd, Moscow 125284

125284 Москва, 2-й Боткинский проезд, 3

https://orcid.org/0000-0002-4385-9048DerzhavinV. A.ДержавинВ. А.
Russian Federation

Vitaly A. Derzhavin.

3 2nd Botkinsky proezd, Moscow 125284

Державин Виталий Андреевич.

125284 Москва, 2-й Боткинский проезд, 3

osteosa@yandex.ruhttps://orcid.org/0000-0002-7944-3108YadrinaA. V.ЯдринаА. В.
Russian Federation

3 2nd Botkinsky proezd, Moscow 125284

125284 Москва, 2-й Боткинский проезд, 3

https://orcid.org/0000-0001-5772-4067ElkhovD. O.ЕлховД. О.
Russian Federation

3 2nd Botkinsky proezd, Moscow 125284

125284 Москва, 2-й Боткинский проезд, 3

P.A. Herzen Moscow Research Oncological Institute – branch of the National Medical Research Center of Radiology, Ministry of Health of RussiaМосковский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России0107202315218242502202301072023Copyright ©; 2023, Bukharov A.V., Erin D.A., Derzhavin V.A., Yadrina A.V., Elkhov D.O.Copyright ©; 2023, Бухаров А.В., Ерин Д.А., Державин В.А., Ядрина А.В., Елхов Д.О.2023Bukharov A.V., Erin D.A., Derzhavin V.A., Yadrina A.V., Elkhov D.O.Бухаров А.В., Ерин Д.А., Державин В.А., Ядрина А.В., Елхов Д.О.https://creativecommons.org/licenses/by/4.0https://sarbon.abvpress.ru/jour/article/view/606

This review presents an analysis of treatment outcomes for patients with metastases of cutaneous melanoma into the regional lymph nodes. Types of surgical interventions currently used in oncological surgery for this pathology are considered, as well as the trends of their future practical application. The results of sentinel lymph node biopsy and regional lymph node dissection in patients with primary tumors with varying thickness and the effect of surgical interventions on treatment effectiveness are presented.

В данном обзоре представлен анализ результатов лечения пациентов с метастазами меланомы кожи в регионарные лимфатические узлы. Рассмотрены используемые в современной онкохирургии варианты хирургических вмешательств при данной патологии, а также тенденции их дальнейшего практического применения. Представлены результаты биопсии сторожевого лимфатического узла и регионарной лимфаденэктомии у пациентов с первичной опухолью различной толщины, а также влияние хирургических вмешательств на эффективность проводимого лечения.

cutaneous melanomalymph node metastasessentinel lymph noderegional lymph node dissectionмеланома кожиметастазы в лимфатические узлысторожевой лимфатический узелрегионарная лимфаденэктомияThe state of oncological care for the population of Russia in 2021. Ed. by A.D. Kaprin, V.V. Starinskiy, A.O. Shahzadova. Moscow: P.A. Herzen MNIOI – branch of the Federal State Budgetary Institution “NMIC of Radiology” of the Ministry of Health of Russia, 2022. 239 p.Состояние онкологической помощи населению России в 2021 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 с.Jemal A., Siegal R., Ward E. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106–30. DOI: 10.3322/canjclin.56.2.106White R.R., Stanley W.E., Johnson J.L. et al. Long-term survival in 2505 patients with melanoma with regional lymph node metastases. Ann Surg 2002;235:879–87. DOI: 10.1097/00000658-200206000-00017Franke V., van Akkooi A.C.J. The extent of surgery for stage III melanoma: How much is appropriate? Lancet Oncol 2019;20:e167–74. DOI: 10.1016/s1470-2045(19)30099-3Snow H. Melanotic cancerous disease. Lancet 1892;2:872. DOI: 10.1016/s0140-6736(01)88090-9Morton D.L., Wen D.R., Wong J.H. et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392–9. DOI: 10.1001/archsurg.1992.01420040034005Karakousis G.C., Gimotty P.A., Czerniecki B.J. Regional nodal metastatic disease is the strongest predictor of survival in patients with thin vertical growth phase melanomas: a case for SLN Staging biopsy in these patients. Ann Surg Oncol 2007;14(5):1596–603. DOI: 10.1245/s10434-006-9319-yEttinger D.S., Wood D.E., Aisner D.L. National Comprehensive Cancer Network Guidelines for Melanoma 2021, version 2.21. J Natl Compr Canc Netw 2021;19(3):254–66. DOI: 10.6004/jnccn.2021.197glupDoubrovsky A., de Wilt J.H.W., Scolyer R.A. Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma. Ann Surg Oncol 2004;11(9):829–36. DOI: 10.1245/aso.2004.01.026Bartlett E.K., Gimotty P.A., Sinnamon A.J. Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy. Ann Surg Oncol 2014;21(2):643–9. DOI: 10.1245/s10434-013-3313-yMurali R., Haydu L.E., Quinn M.J. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma. Ann Surg 2012;255(1):128–33. DOI: 10.1097/sla.0b013e3182306c72Whiteman D.C., Baade P.D., Olsen C.M. More people die from thin melanomas (1 mm) than from thick melanomas (>4 mm) in Queens-land, Australia. J Invest Dermatol 2015;135(4):1190–3. DOI: 10.1038/jid.2014.452Han D., Zager J.S., Shyr Y. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol 2013;31(35):4387–93. DOI: 10.1200/jco.2013.50.1114Taylor R.C., Patel A., Panageas K.S. et al. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 2007;25(7):869–75. DOI: 10.1200/jco.2006.08.9755Morton D.L., Thompson J.F., Cochran A.J. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355(13):1307–17. DOI: 10.1056/nejmoa060992Morton D.L., Thompson J.F., Cochran A.J. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014;370(7):599–609. DOI: 10.1056/nejmoa1310460Susok L., Nick C., Becker J.C. et al. Waiving subsequent complete lymph node dissection in melanoma patients with positive sentinel lymph node does not result in worse outcome on 20-year analysis. Cancers 2021;13(21):5425. DOI: 10.3390/cancers13215425Bartlett E.K., Lee A.Y., Spanheimer P.M. et al. Nodal and systemic recurrence following observation of a positive sentinel lymph node in melanoma. BJS 2020;107(11):1480–8. DOI: 10.1002/bjs.11621Garbe C., Peris K., Hauschild A. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline – update 2012. Eur J Cancer 2012;48(15):2375–90. DOI: 10.1016/j.ejca.2012.06.013Bartlett E.K., Peters M.G., Blair A. Identification of patients with intermediate thickness melanoma at low risk for sentinel lymph node positivity. Ann Surg Oncol 2016;23(1):250–6. DOI: 10.1245/s10434-015-4766-yChang J.M., Kosiorek H.E., Dueck A.C. Stratifying SLN incidence in intermediate thickness melanoma patients. Am J Surg 2018;215(4):699–706. DOI: 10.1016/j.amjsurg.2017.12.009Mozzillo N., Pennacchioli E., Gandini S. Sentinel node biopsy in thin and thick melanoma. Ann Surg Oncol 2013;20(8):2780–6. DOI: 10.1245/s10434-012-2826-0Ribero S., Osella-Abate S., Sanlorenzo M. Sentinel lymph node biopsy in thick-melanoma patients (n = 350): what is its prognostic role? Ann Surg Oncol 2015;22(6):1967–73. DOI: 10.1245/s10434-014-4211-7Yamamoto M., Fisher K.J., Wong J.Y. Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma. Cancer 2015;121(10):1628–36. DOI: 10.1002/cncr.29239Leiter U., Stadler R., Mauch C. et al. Final analysis of DeCOG-SLT Trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol 2019;37(32):3000–8. DOI: 10.1200/JCO.18.02306Faries M.B., Thompson J.F., Cochran A.J. et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 2017;376(23):2211–22. DOI: 10.1056/NEJMoa1613210Clinical recommendations of the Association of Oncologists of Russia for the treatment of skin melanoma. 2021. Pp. 37, 42. (In Russ.).Клинические рекомендации Ассоциации онкологов России по лечению меланомы кожи. 2021. С. 37, 42.Gershenwald J.E., Scolyer R.A. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol 2018;25(8):2105–10. DOI: 10.1245/s10434-018-6513-7Coit D.G., Brennan M.F. Extent of lymph node dissection in melanoma of the trunk or lower extremity. Arch Surg 1989;124(2):162–6. DOI: 10.1001/archsurg.1989.01410020032004Mann G.B., Coit D.G. Does the extent of operation influence the prognosis in patients with melanoma metastatic to inguinal nodes? Ann Surg Oncol 1999;6(3):263–71. DOI: 10.1007/s10434-999-0263-5Strobbe L.J., Jonk A., Hart A.A. et al. The value of Cloquet’s node in predicting melanoma nodal metastases in the pelvic lymph node basin. Ann Surg Oncol 2001;8(3):209–14. DOI: 10.1007/s10434-001-0209-zEssner R., Scheri R., Kavanagh M. et al. Surgical management of the groin lymph nodes in melanoma in the era of sentinel lymph node dissection. Arch Surg 2006;141:877–84. DOI: 10.1001/archsurg.141.9.877Kretschmer L., Neumann C., Preusser K.P., Marsch W.C. Superficial inguinal and radical ilioinguinal lymph node dissection in patients with palpable melanoma metastases to the groin – an analysis of survival and local recurrence. Acta Oncol 2001;40(1):72–8. DOI: 10.1080/028418601750071091Meyer T., Merkel S., Gohl J., Hohenberger W. Lymph node dissection for clinically evident lymph node metastases of malignant melanoma. Eur J Surg Oncol 2002;28(4):424–30. DOI: 10.1053/ejso.2001.1262Oude Ophuis C.M.C., van Akkooi A.C.J., Hoekstra H.J. et al. Risk factors for positive deep pelvic nodal involvement in patients with palpable groin melanoma metastases: can the extent of surgery be safely minimized? Ann Surg Oncol 2015;22:S1172–80. DOI: 10.1245/s10434-015-4602-4Spillane A.J., Haydu L., McMillan W. et al. Quality assurance parameters and predictors of outcome for ilioinguinal and inguinal dissection in a contemporary melanoma patient population. Ann Surg Oncol 2011;18(9):2521–8. DOI: 10.1245/s10434-011-1755-7Santinami M., Carbone A., Crippa F. et al. Radical dissection after positive groin sentinel biopsy in melanoma patients: rate of further positive nodes. Melanoma Res 2009;19(2):112–8. DOI: 10.1097/cmr.0b013e328329fe7dGlover A.R., Allan C.P., Wilkinson M.J. et al. Outcomes of routine ilioinguinal lymph node dissection for palpable inguinal melanoma nodal metastasis. Br J Surg 2014;101(7):811–9. DOI: 10.1002/bjs.9502Egger M.E., Brown R.E., Roach B.A. Addition of an iliac/obturator lymph node dissection does not improve nodal recurrence or survival in melanoma. J Am Coll Surg 2014;219(1):101–8. DOI: 10.1016/j.jamcollsurg.2014.02.019Van der Ploeg A.P., van Akkooi A.C., Schmitz P.I. Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection. Ann Surg Oncol 2011;18(12):3300–8. DOI: 10.1245/s10434-011-1741-0Karakousis C.P., Emrich L.J., Rao U. Groin dissection in malignant melanoma. Am J Surg 1986;152(5):491–5. DOI: 10.1016/0002-9610(86)90211-4Badgwell B., Xing Y., Gershenwald J.E. et al. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Ann Surg Oncol 2007;14(10):2867–75. DOI: 10.1245/s10434-007-9512-7Allan C.P., Hayes A.J., Thomas J.M. Ilioinguinal lymph node dissection for palpable metastatic melanoma to the groin. ANZ J Surg 2008;78(11):982–6. DOI: 10.1111/j.1445-2197.2008.04716.xNowecki Z.I., Rutkowski P., Michej W. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2–pT3). Ann Surg Oncol 2008;15(8):2223–34. DOI: 10.1245/s10434-008-9965-3Niebling M.G., Wevers K.P., Suurmeijer A.J. et al. Deep lymph node metastases in the groin significantly affects prognosis, particularly in sentinel node-positive melanoma patients. Ann Surg Oncol 2015;22(1):279–86. DOI: 10.1245/s10434-014-3854-8Balch C.M., Gershenwald J.E., Soong S.J. et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010;28(14):2452–9. DOI: 10.1200/jco.2009.27.1627